Drug Trial Radar · NCT05968430
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,076
Actual
Start
Jul 14, 2023
Primary completion
Dec 30, 2025
Study completion May 2027
Sponsor
- Lead sponsor
- Mineralys Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the long-term safety, efficacy and tolerability of lorundrostat (an aldosterone synthase inhibitor) in subjects with hypertension
Conditions
- Hypertension
Interventions
lorundrostatDrug
Tablet, administered orally
PlaceboDrug
Tablet, administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from MLS-101-301 baseline automated office blood pressureTime frame: Week 36
- Change at MLS-101-901 Week 16 (RTW Week 4) from MLS 101-901 Week 12 (RTW substudy baseline) in AOBP SBP in subjects enrolled in RTWTime frame: Week 16
Locations
177 sites in 13 countries. Site status is shown where the registry gives one.
Accel Research Sites (ARS) - Birmingham Clinical Research Unit
Birmingham, Alabama
G & L Research LLC
Foley, Alabama
Chandler Clinical Trials
Chandler, Arizona
Arizona Kidney
Glendale, Arizona
AKDHC Medical Research Services, AZ
Phoenix, Arizona
Noble Clinical Research
Tucson, Arizona
Del Sol Research Management, LLC
Tucson, Arizona
Entertainment Medical Group, Inc
Beverly Hills, California
CA Institute of Renal Research, CA
Chula Vista, California
Amicis Research Center - Vacaville
Fairfield, California
Amicis Research Center - Granada Hills
Granada Hills, California
Marvel Clinical Research 002, LLC
Huntington Beach, California
University of California San Diego (UCSD) - Altman Clinical and Translational Research Institute (ACTRI)
La Jolla, California
Clinical Trials Research (CTR) - Lincoln
Lincoln, California
Academic Medical Research Institute (AMRI) - Los Angeles
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
Amicis Research Center - Mission Hills
Northridge, California
Amicis Research Center-Northridge
Northridge, California
Northridge Clinical Trials
Northridge, California
Pasadena Clinical Trials
Pasadena, California
Empire Clinical Research
Pomona, California
Clinical Trials Research (CTR) - Sacramento
Sacramento, California
Triwest Research Associates
San Diego, California
San Jose Clinical Trials
San Jose, California
Amicis Research Center - Valencia
Valencia, California
Kidney & Hypertension Center - Victorville
Victorville, California
Blue Coast Research Center (BCRC)
Vista, California
Accelerated Enrollment Solutions (AES) -Vista/Synexus (Radiant Research)
Vista, California
Colorado Kidney (Denver) Nephrology
Denver, Colorado
CMR of Greater New Haven
Hamden, Connecticut
Qway Research
Hialeah, Florida
Indago Research and Health Center
Hialeah, Florida
Clinical Neuroscience Solutions, Inc
Jacksonville, Florida
Nuovida Research Center Corp
Miami, Florida
Clinical Neuroscience Solutions, Inc
Orlando, Florida
Nephrology Associates of Central Florida
Orlando, Florida
AES - Orlando
Orlando, Florida
Pines Care Research Center
Pembroke Pines, Florida
Patron Medical - Andres Patron D.O. (Patron Ventures, LLC)
Pembroke Pines, Florida
Progressive Medical Research
Port Orange, Florida
Showing 40 of 177 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.